FDA Announces New Tool for Clinical Laboratories to Identify Validated Supply Alternatives for SARS-CoV-2 Testing
![Clinical laboratory testing supplies, such as primers and probes, master mix, collection and media, and general reagents. Photo snaps source FDA supply tool.](https://covid19briefings.com/wp-content/uploads/2020/06/AS_255771503-lab-test-supply-substitution-graphic-flat-1.jpg)
As of June 12, 2020, the FDA had authorized 135 COVID-19 tests under emergency use authorization (EUA), which include 114 molecular tests, 20 antibody tests, and 1 antigen test. The FDA has also released a new interactive tool designed to assist in identifying COVID-19 testing supply deficiencies and alternatives.
Clinical Laboratories Face Reimbursement Uncertainties Over SARS-CoV-2 Testing for Asymptomatic Individuals
![A drive up COVID-19 testing site, June 2020, at an empty pharmacy in Birmingham, Alabama](https://covid19briefings.com/wp-content/uploads/2020/06/drive-up-testing-covid19-birmingham-alabama-june-2020-covid19-stat-liz-carey-sm.jpg)
In an exclusive interview, Danielle Sloane of Bass, Berry and Sims, discusses potentially tricky reimbursement for SARS-CoV-2 asymptomatic testing.